Characteristics and Dosing Patterns of Tirzepatide Users with Type 2 Diabetes in the United States
Patients with T2D initiating tirzepatide had multimorbidity; uncontrolled diabetes; and mean BMI was consistent with Class 2 obesity. Patients showed favorable tirzepatide adherence and persistence profiles, and the majority remained at <10 mg doses during the 6-month follow-up period.
Authors
- Reema Mody (ORCID: https://orcid.org/0000-0002-3442-1714)
- Gally Reznor
- Brian D. Benneyworth (ORCID: https://orcid.org/0000-0002-4692-5303)
- Grace Stockbower
- Michael Grabner (ORCID: https://orcid.org/0000-0002-6521-1007)
- Chia‐Chen Teng
- Karishma Desai (ORCID: https://orcid.org/0000-0001-6108-4154)
Institutions
- Eli Lilly (United States) (US)
- Wilmington University (US)
Publication Details
- Journal
- Diabetes Therapy
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1007/s13300-024-01684-6
- Citations
- 7
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 9.06
Funders
- Eli Lilly and Company